GLP-1 receptor agonist with 97% homology to native GLP-1 and an acylated fatty acid chain for albumin binding. Reduces appetite, slows gastric emptying, and improves glycemic control. FDA-approved for obesity and type 2 diabetes.
Inject SubQ daily at same time. Titrate: 0.6mg x1wk → 1.2mg x1wk → 1.8mg x1wk → 2.4mg x1wk → 3mg. Slow titration minimizes nausea.
Log doses, calculate reconstitution, set reminders, and get AI guidance for Liraglutide.
Start Free Trial